Memory T cell responses targeting the SARS coronavirus persist up to 11 years post-infection

Vaccine

Volumn 34, Issue 17, 2016, Pages 2008-2014

  Ng, Oi Wing ^a   Chia, Adeline ^b   Tan, Anthony T ^b   Jadi, Ramesh S ^a   Leong, Hoe Nam ^c   Bertoletti, Antonio ^b,d   Tan, Yee Joo ^a,e  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^b DUKE NUS MEDICAL SCHOOL   (Singapore)

^c SINGAPORE GENERAL HOSPITAL   (Singapore)

^d AGENCY FOR SCIENCE   (Singapore)

^e INSTITUTE OF MOLECULAR AND CELL BIOLOGY   (Singapore)

Author keywords

Epitope; Immunity; SARS CoV; T cell

Indexed keywords

EPITOPE; GAMMA INTERFERON; HLA ANTIGEN CLASS 1; NUCLEOCAPSID PROTEIN; STRUCTURAL PROTEIN; VIRUS ENVELOPE PROTEIN; M PROTEIN, CORONAVIRUS; MATRIX PROTEIN; NUCLEOCAPSID PROTEIN, CORONAVIRUS;

ALLOGENEIC RESTRICTION; AMINO ACID SEQUENCE; ARTICLE; CASE REPORT; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CONTROLLED STUDY; CROSS REACTION; CYTOKINE PRODUCTION; ENZYME LINKED IMMUNOSPOT ASSAY; EPITOPE MAPPING; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNOLOGICAL MEMORY; MEMORY T LYMPHOCYTE; MIDDLE EAST RESPIRATORY SYNDROME CORONAVIRUS; PRIORITY JOURNAL; SARS CORONAVIRUS; SCREENING; SEVERE ACUTE RESPIRATORY SYNDROME; IMMUNOLOGY;

CD8-POSITIVE T-LYMPHOCYTES; CROSS REACTIONS; EPITOPES, T-LYMPHOCYTE; HISTOCOMPATIBILITY ANTIGENS CLASS I; HUMANS; IMMUNITY, CELLULAR; IMMUNOLOGIC MEMORY; MIDDLE EAST RESPIRATORY SYNDROME CORONAVIRUS; NUCLEOCAPSID PROTEINS; SARS VIRUS; SEVERE ACUTE RESPIRATORY SYNDROME; VIRAL MATRIX PROTEINS;

EID: 84960153680     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2016.02.063     Document Type: Article

References (31)

1. Ksiazek T.G., Erdman D., Goldsmith C.S., Zaki S.R., Peret T., Emery S., et al. A novel coronavirus associated with severe acute respiratory syndrome. N Engl J Med 2003, 348(20 (May)):1953-1966.
2. Peiris J.S., Guan Y., Yuen K.Y. Severe acute respiratory syndrome. Nat Med 2004, 10(12 Suppl. (December)):S88-S97.
3. Li W., Shi Z., Yu M., Ren W., Smith C., Epstein J.H., et al. Bats are natural reservoirs of SARS-like coronaviruses. Science 2005, 310(5748 (October)):676-679.
4. Lau S.K., Woo P.C., Li K.S., Huang Y., Tsoi H.W., Wong B.H., et al. Severe acute respiratory syndrome coronavirus-like virus in Chinese horseshoe bats. Proc Natl Acad Sci U S A 2005, 102(39 (September)):14040-14045.
5. Ge X.Y., Li J.L., Yang X.L., Chmura A.A., Zhu G., Epstein J.H., et al. Isolation and characterization of a bat SARS-like coronavirus that uses the ACE2 receptor. Nature 2013, 503(7477 (November)):535-538.
6. Guan Y., Zheng B.J., He Y.Q., Liu X.L., Zhuang Z.X., Cheung C.L., et al. Isolation and characterization of viruses related to the SARS coronavirus from animals in southern China. Science 2003, 302(5643 (October)):276-278.
7. Rota P.A., Oberste M.S., Monroe S.S., Nix W.A., Campagnoli R., Icenogle J.P., et al. Characterization of a novel coronavirus associated with severe acute respiratory syndrome. Science 2003, 300(5624 (May)):1394-1399.
8. + T cells are important in control of SARS-CoV infection. J Virol 2010, 84(3 (February)):1289-1301.
9. Zhao J., Perlman S. T cell responses are required for protection from clinical disease and for virus clearance in severe acute respiratory syndrome coronavirus-infected mice. J Virol 2010, 84(18 (September)):9318-9325.
10. Channappanavar R., Fett C., Zhao J., Meyerholz D.K., Perlman S. Virus-specific memory CD8T cells provide substantial protection from lethal severe acute respiratory syndrome coronavirus infection. J Virol 2014, 88(19 (October)):11034-11044.
11. Li T., Qiu Z., Zhang L., Han Y., He W., Liu Z., et al. Significant changes of peripheral T lymphocyte subsets in patients with severe acute respiratory syndrome. J Infect Dis 2004, 189(4 (February)):648-651.
12. Cameron M.J., Bermejo-Martin J.F., Danesh A., Muller M.P., Kelvin D.J. Human immunopathogenesis of severe acute respiratory syndrome (SARS). Virus Res 2008, 133(1 (April)):13-19.
13. Oh H.L., Chia A., Chang C.X., Leong H.N., Ling K.L., Grotenbreg G.M., et al. Engineering T cells specific for a dominant severe acute respiratory syndrome coronavirus CD8T cell epitope. J Virol 2011, 85(20 (October)):10464-10471.
14. Case Definitions for Surveillance of Severe Acute Respiratory Syndrome (SARS). 2003 [Available from: ]. http://www.who.int/csr/sars/casedefinition/en/.
15. Li T., Xie J., He Y., Fan H., Baril L., Qiu Z., et al. Long-term persistence of robust antibody and cytotoxic T cell responses in recovered patients infected with SARS coronavirus. PLoS ONE 2006, 1:e24.
16. Li C.K., Wu H., Yan H., Ma S., Wang L., Zhang M., et al. T cell responses to whole SARS coronavirus in humans. J Immunol 2008, 181(8 (October)):5490-5500.
17. Yang L.T., Peng H., Zhu Z.L., Li G., Huang Z.T., Zhao Z.X., et al. Long-lived effector/central memory T-cell responses to severe acute respiratory syndrome coronavirus (SARS-CoV) S antigen in recovered SARS patients. Clin Immunol 2006, 120(2 (August)):171-178.
18. Zhou M., Xu D., Li X., Li H., Shan M., Tang J., et al. Screening and identification of severe acute respiratory syndrome-associated coronavirus-specific CTL epitopes. J Immunol 2006, 177(4 (August)):2138-2145.
19. + T cells by a flow cytometric assay for degranulation. J Immunol Methods 2003, 281(1-2 (October)):65-78.
20. Harding C.V., Geuze H.J. Antigen processing and intracellular traffic of antigens and MHC molecules. Curr Opin Cell Biol 1993, 5(4 (August)):596-605.
21. Liu J., Sun Y., Qi J., Chu F., Wu H., Gao F., et al. The membrane protein of severe acute respiratory syndrome coronavirus acts as a dominant immunogen revealed by a clustering region of novel functionally and structurally defined cytotoxic T-lymphocyte epitopes. J Infect Dis 2010, 202(8 (October)):1171-1180.
22. Fan Y.Y., Huang Z.T., Li L., Wu M.H., Yu T., Koup R.A., et al. Characterization of SARS-CoV-specific memory T cells from recovered individuals 4 years after infection. Arch Virol 2009, 154(7):1093-1099.
23. Tsao Y.P., Lin J.Y., Jan J.T., Leng C.H., Chu C.C., Yang Y.C., et al. HLA-ATsao Y.P.0201 T-cell epitopes in severe acute respiratory syndrome (SARS) coronavirus nucleocapsid and spike proteins. Biochem Biophys Res Commun 2006, 344(1 (May)):63-71.
24. Kim T.W., Lee J.H., Hung C.F., Peng S., Roden R., Wang M.C., et al. Generation and characterization of DNA vaccines targeting the nucleocapsid protein of severe acute respiratory syndrome coronavirus. J Virol 2004, 78(9 (May)):4638-4645.
25. + T cell determinants during human viral infection in populations of Asian ethnicity. J Immunol 2013, 191(8 (October)):4010-4019.
26. Zaki A.M., van Boheemen S., Bestebroer T.M., Osterhaus A.D., Fouchier R.A. Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia. N Engl J Med 2012, 367(19 (November)):1814-1820.
27. de Groot R.J., Baker S.C., Baric R.S., Brown C.S., Drosten C., Enjuanes L., et al. Middle East respiratory syndrome coronavirus (MERS-CoV): announcement of the Coronavirus Study Group. J Virol 2013, 87(14 (July)):7790-7792.
28. Chan J.F., Lau S.K., To K.K., Cheng V.C., Woo P.C., Yuen K.Y. Middle East respiratory syndrome coronavirus: another zoonotic betacoronavirus causing SARS-like disease. Clin Microbiol Rev 2015, 28(2 (April)):465-522.
29. Cheng V.C., Lau S.K., Woo P.C., Yuen K.Y. Severe acute respiratory syndrome coronavirus as an agent of emerging and reemerging infection. Clin Microbiol Rev 2007, 20(4 (October)):660-694.
30. van Boheemen S., de Graaf M., Lauber C., Bestebroer T.M., Raj V.S., Zaki A.M., et al. Genomic characterization of a newly discovered coronavirus associated with acute respiratory distress syndrome in humans. MBio 2012, 3(6).
31. Martin J.E., Louder M.K., Holman L.A., Gordon I.J., Enama M.E., Larkin B.D., et al. A SARS DNA vaccine induces neutralizing antibody and cellular immune responses in healthy adults in a Phase I clinical trial. Vaccine 2008, 26(50 (November)):6338-6343.